Form 8-K - Current report - Item 5.07 Item 8.01

Aclarion Inc

Announcement: ACON 8-K Special Filing

Form 8-K - Current report - Item 4.01 Item 9.01

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

Aclarion provides critical insights for low back pain treatments##: 
Aclarion, Inc. leverages Magnetic Resonance Spectroscopy, signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments for low back pain. With Nociscan, Aclarion provides physicians with critical insights of the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. In 2022, the healthcare technology company had cash of about $1.5 million enough to fund their operating expenses into Q2 2023. The company's ability to generate revenue that can sustain profitability depends heavily on the commercialization and continued development of their SaaS platform.

AAA
Aclarion's forward-looking strategy involves securing payer contracts to cover Category III CPT codes, initiating studies and creating real-world evidence, and hiring additional personnel to support the above programs. They also plan to raise additional working capital through public offerings and strategic transactions. They believe that favorable payer coverage will foster adoption for their technology by physicians and imaging centers. Despite the COVID-19 pandemic, the company has not experienced any interruption in their product marketing or developments.

Announcement: ACON 10-K Annual Report

Form 8-K - Current report - Item 1.01 Item 3.02 Item 5.03 Item 9.01

CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK DATED FEBRUARY 16, 2023

SECURITIES PURCHASE AGREEMENT DATED FEBRUARY 16, 2023 BETWEEN ACLARION, INC. AND